BML-190

Discontinued Product

BML-190 (Cat. No. 1383) has been withdrawn from sale for commercial reasons.
Cat.No. 1383 - BML-190 | C23H23ClN2O4 | CAS No. 2854-32-2
Description: Potent, selective CB2 ligand
Alternative Names: Indomethacin morpholinylamide, IMMA
Chemical Name: 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1-[2-(4-morpholinyl)-2-oxoethyl]-1H-indole
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature

Biological Activity

Potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).

Technical Data

M. Wt 426.9
Formula C23H23ClN2O4
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 2854-32-2
PubChem ID 2415
InChI Key BJSDNVVWJYDOLK-UHFFFAOYSA-N
Smiles COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(=O)N3CCOCC3)C2=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Melck et al (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 118 PMID: 10614630

Gallant et al (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg.Med.Chem.Lett. 6 2263

View Related Products by Target

Keywords: BML-190, BML-190 supplier, Potent, selective, CB2, ligands, Cannabinoid, Receptors, cb2r, Indomethacin, morpholinylamide, IMMA, 1383, Tocris Bioscience

1 Citation for BML-190

Citations are publications that use Tocris products. Selected citations for BML-190 include:

Zhang et al (2010) In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes. Eur J Pharm Sci 41 163 PMID: 20542112


Reviews for BML-190

There are currently no reviews for this product. Be the first to review BML-190 and earn rewards!

Have you used BML-190?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Cannabinoid Receptor Ligands

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.